Applied Filters
Post-grant patent challenges in Europe and the US: harmony at last?
Challenging the validity of a patent through the court systems of Europe and the US can be a time-consuming and expensive process. Jane Wainwright and Daniel Young look at the alternatives.
Generic battles: pay-for-delay in Brazil
While no court has tested it, Brazilian legislation seems to prohibit pay-for-delay settlements in the pharmaceutical industry. Gabriel Di Blasi argues that it’s time for a test case.
Who's first? New rules on filing patents
On March 16, 2013, the ‘first inventor to file’ provisions of the AIA came into effect. MaryAnne Armstrong looks at the implications.
Moving forward: biologics and biocomparables in Mexico
Biocomparable medicines are currently among the hottest topics in regard to life sciences legislation in Mexico. Daniel Sánchez and Victor Ramirez investigate.
Waiting to inhale: MannKind's diabetes strategy
For a young innovation company, IP protection is all about ensuring comprehensive coverage. LSIPR spoke to David Diamond of MannKind Corporation about its threats and opportunities.
Myriad: Keeping a low profile
The latest rulings in the controversial legal battle over breast cancer gene patents seem to have found two out of three issues in defendant Myriad Genetics’ favour, but legal counsel Ben Jackson isn’t too excited by the implications.
A step forward: new dosage patents in Mexico?
The status of patentability for new dosage regimes in Mexico is unclear, but there have been some positive signs, says Pablo Fuentes.
A question of fairness: preliminary injunctions in Mexico
The system governing preliminary injunctions for pharmaceutical patent infringement should be revised to stave off potential frivolous cases, say Hedwig Lindner and Manuel Morante.
Crossed wires: protecting medicines in Mexico
When introducing medicinal products to any market, the strength of the trademark is crucial. But the Mexican system requires getting trademark approval from two different authorities.
Out in front: the Boston cluster
When it comes to life sciences, Boston is out on its own. LSIPR takes a look at innovation in the Olde Towne.
